Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
AstraZeneca
UBS
Mallinckrodt
Federal Trade Commission

Generated: September 23, 2019

DrugPatentWatch Database Preview

Details for Patent: 9,877,933

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,877,933 protect, and when does it expire?

Patent 9,877,933 protects GOCOVRI and is included in one NDA.

This patent has seventeen patent family members in seven countries.

Summary for Patent: 9,877,933
Title:Method of administering amantadine prior to a sleep period
Abstract: Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine that are suitable for nighttime administration.
Inventor(s): Went; Gregory T. (Mill Valley, CA), Sathyan; Gayatri (Bangalore, IN), Vermani; Kavita (Fremont, CA), Ganapati; Gangadhara (Palo Alto, CA), Coffee; Michael (Tiburon, CA), Shek; Efraim (Pleasanton, CA), Katdare; Ashok (Berkeley, CA)
Assignee: Adamas Pharma, LLC (Emeryville, CA)
Application Number:15/428,878
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,877,933
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form;

Drugs Protected by US Patent 9,877,933

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Adamas Pharma GOCOVRI amantadine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 208944-001 Aug 24, 2017 RX Yes No ➤ Sign Up ➤ Sign Up TREATMENT OF DYSKINESIA AND INCREASING ON TIME WITHOUT TROUBLESOME DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS ➤ Sign Up
Adamas Pharma GOCOVRI amantadine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 208944-002 Aug 24, 2017 RX Yes Yes ➤ Sign Up ➤ Sign Up TREATMENT OF DYSKINESIA AND INCREASING ON TIME WITHOUT TROUBLESOME DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS ➤ Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,877,933

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2010325960 ➤ Sign Up
Australia 2015202356 ➤ Sign Up
Canada 2782556 ➤ Sign Up
Canada 2994873 ➤ Sign Up
China 102883601 ➤ Sign Up
China 106389381 ➤ Sign Up
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Harvard Business School
McKesson
UBS
Merck
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.